tradingkey.logo
搜尋

Telomir Pharmaceuticals Inc

TELO
添加自選
1.270USD
-0.030-2.31%
收盤 07/02, 13:00美東報價延遲15分鐘
43.66M總市值
虧損本益比TTM

Telomir Pharmaceuticals Inc

1.270
-0.030-2.31%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.31%

5天

+2.42%

1月

0.00%

6月

-5.22%

今年開始到現在

-4.51%

1年

+10.43%

關鍵數據
1.310今開
1.340最高
47.05K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.14%換手率
1.300昨收
1.270最低
45.72K成交額
虧損本益比靜
8.80市淨率
0.00%股息率 TTM
-293.73%ROA
3.10052週最高
1.21量比
-16.53M淨利潤
34.38M總股本
-0.2846每股盈餘TTM
--Beta
-384.26%ROE
1.05052週最低
5.38%振幅
--毛利率
43.66M總市值
0.51回報/風險
4.63%風險率

TradingKey Telomir Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Telomir Pharmaceuticals Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在藥品行業排名133/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為15.50。中期看,股價處於平穩狀態。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Telomir Pharmaceuticals Inc評分

相關信息

行業排名
133 / 157
全市場排名
512 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Telomir Pharmaceuticals Inc亮點

亮點風險
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
估值合理
公司最新PE估值-4.46,處於3年歷史合理位
機構加倉
最新機構持股3.42M股,環比增加12.50%

分析師目標

基於 0 分析師
--
評級
15.500
目標均價
+1120.47%
漲幅空間

Telomir Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Telomir Pharmaceuticals Inc簡介

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
公司代碼TELO
公司Telomir Pharmaceuticals Inc
CEOAminov (Erez)
網址https://telomirpharma.com/

常見問題

Telomir Pharmaceuticals Inc(TELO)的當前股價是多少?

Telomir Pharmaceuticals Inc(TELO)的當前股價是 1.27。

Telomir Pharmaceuticals Inc 的股票代碼是什麼?

Telomir Pharmaceuticals Inc的股票代碼是TELO。

Telomir Pharmaceuticals Inc股票的52週最高點是多少?

Telomir Pharmaceuticals Inc股票的52週最高點是3.10。

Telomir Pharmaceuticals Inc股票的52週最低點是多少?

Telomir Pharmaceuticals Inc股票的52週最低點是1.05。

Telomir Pharmaceuticals Inc的市值是多少?

Telomir Pharmaceuticals Inc的市值是42.97M。

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是多少

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是-0.33。